Scott Schoenhaus

“Can you talk about more in detail what you're doing here on the enhanced targeting side, And if you expect to see the activity and Marketplace growth to further accelerate from here, given what you're seeing and doing.”

“So you mentioned that Predictive Talks is now being included in ACV, and I know part of your growth strategy was to unlock more pharma budgets by expanding product scope and capabilities.”

“And following up on Cylinder, it looks like there's a large diagnostics side to this acquisition. Maybe talk about how that is going to be monetized on your platform and maybe talk about future growth opportunities within diagnostics, if this is the launching point.”

“Maybe if I can build a little bit on Ryan's question, thinking about the end market.”

“So I wanted to talk about the new My Green program. I guess, Dan, you talked about, obviously, you think 12% to 15% yield was your prior kind of ceiling. Maybe talk about where that is now with the migraine program.”